AXON Sio Gene Therapies Inc

Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"

Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"

      - Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists

NEW YORK and BASEL, Switzerland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the company will provide a corporate overview and participate in 1:1 meetings at upcoming virtual investor and patient conferences in September. Additionally, the company announced plans for their 1st Parkinson’s Disease R&D Day with key opinion leaders.

Investor and Patient Conference Presentation details:         

Baird Global Healthcare Conference  
Date:Wednesday, September 9, 2020
Time:9:40 AM ET
  
2020 Virtual GM1 Family Meeting 
Date:Thursday, September 10, 2020
Time:6:45 PM ET
Registration Link: 
  
Cantor Fitzgerald Virtual Global Healthcare Conference 
Date:Thursday, September 17, 2020
Time:1:20 PM ET
Webcast link:
  
20th Annual Biotech in Europe Forum 
Date:Thursday, September 24, 2020
Time:9:00 AM ET
Registration link: 
  
AXO-Lenti-PD Parkinson’s Disease R&D Day  
Date:Friday, October 30, 2020
Moderator: Gavin Corcoran, MD, Chief R&D Officer, Axovant Gene Therapies
Additional details to be provided later in September.

A live webcast of the presentations will be available in the Events section of Axovant's website at . A replay will be available for approximately 30 days following the conference.

About Axovant Gene Therapies

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit .

Contacts:

Media & Investors

Parag Meswani

Axovant Gene Therapies Ltd.

(212) 547-2523



Source: Axovant Gene Therapies 

EN
08/09/2020

Underlying

AXONSio Gene Therapies Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sio Gene Therapies Inc

 PRESS RELEASE
Free
AXON Sio Gene Therap...

Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort o...

Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangliosidosis On-track to report topline results from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the first patient has been dosed in the high-dose cohort of the Phase 1/2 (“Stage 1”) study for Type I (infant...

December 2, 2020 1 EN
 PRESS RELEASE
Free
AXON Sio Gene Therap...

Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D.,...

Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor A pioneering researcher, Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapyDr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of the top 20 translational researchers by Nature Biotechnology NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to...

November 19, 2020 1 EN
 PRESS RELEASE
Free
AXON Sio Gene Therap...

Sio Gene Therapies Announces Corporate Updates and Financial Results f...

Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020 Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseasesCompleted rebranding to Sio Gene Therapies as part of corporate transformation aligning corporate structure and governance with current and future business activityCompany had $63.2 million of cash and cash equivalents as of September 30, 2020, with sufficient cash runway into Q4 2021 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 13,...

November 13, 2020 1 EN
 PRESS RELEASE
Free
AXON Sio Gene Therap...

Axovant Gene Therapies Announces Name Change to Sio Gene Therapies

Axovant Gene Therapies Announces Name Change to Sio Gene Therapies Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicinesCompany’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today announced it will change its name to Sio Gene Therapies, Inc., effective ...

November 10, 2020 1 EN
 PRESS RELEASE
Free
AXON Sio Gene Therap...

Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 ...

Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseasesRepresents Axovant’s second IND clearance for a gene therapy program in the last 12 months NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold and cleared the Investigati...

November 9, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch